← Back to Screener
argenx SE American Depositary Shares (ARGX)
Price$834.45
Favorite Metrics
Price vs S&P 500 (26W)-5.85%
Price vs S&P 500 (4W)11.51%
Market Capitalization$44.42B
P/E Ratio (Annual)40.44x
All Metrics
P/CF (Annual)76.26x
Book Value / Share (Quarterly)$118.34
P/TBV (Annual)8.01x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)116.21%
Cash Flow / Share (Quarterly)$5.05
Price vs S&P 500 (YTD)-3.23%
Gross Margin (TTM)150.91%
Net Profit Margin (TTM)49.40%
EPS (TTM)$31.07
10-Day Avg Trading Volume0.10M
EPS Excl Extra (TTM)$31.07
Revenue Growth (5Y)151.52%
EPS (Annual)$19.57
ROI (Annual)15.04%
Gross Margin (Annual)89.14%
Net Profit Margin (5Y Avg)-41.95%
Cash / Share (Quarterly)$71.75
P/E Basic Excl Extra (TTM)25.48x
Revenue Growth QoQ (YoY)74.12%
P/E Normalized (Annual)40.44x
ROA (Last FY)13.43%
Revenue Growth TTM (YoY)89.56%
EBITD / Share (TTM)$27.11
ROE (5Y Avg)-13.95%
Operating Margin (TTM)41.91%
Cash Flow / Share (Annual)$-2.49
P/B Ratio7.14x
P/B Ratio (Quarterly)7.05x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)21.84x
Net Interest Coverage (TTM)-81.88x
ROA (TTM)19.39%
EPS Growth QoQ (YoY)68.35%
EV / EBITDA (TTM)37.64x
EPS Incl Extra (Annual)$19.57
Current Ratio (Annual)7.29x
Quick Ratio (Quarterly)4.62x
3-Month Avg Trading Volume0.10M
52-Week Price Return36.05%
EV / Free Cash Flow (Annual)85.10x
P/E Incl Extra (TTM)25.48x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$113.94
P/S Ratio (Annual)12.59x
Asset Turnover (Annual)0.35x
52-Week High$810.00
Operating Margin (5Y Avg)-51.15%
EPS Excl Extra (Annual)$19.57
CapEx CAGR (5Y)85.11%
Tangible BV CAGR (5Y)36.18%
26-Week Price Return2.90%
Quick Ratio (Annual)6.40x
13-Week Price Return2.98%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)5.23x
Enterprise Value$48,808.441
Revenue / Share Growth (5Y)133.37%
Asset Turnover (TTM)0.28x
Book Value / Share Growth (5Y)26.80%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)0.63x
Pretax Margin (Annual)30.80%
Cash / Share (Annual)$55.61
3-Month Return Std Dev30.68%
Net Income / Employee (TTM)$1
ROE (Last FY)15.15%
Net Interest Coverage (Annual)5.58x
EPS Basic Excl Extra (Annual)$19.57
P/FCF (TTM)167.05x
Receivables Turnover (TTM)3.72x
EV / Free Cash Flow (TTM)158.10x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$31.07
Receivables Turnover (Annual)3.54x
ROI (TTM)22.76%
P/S Ratio (TTM)12.59x
Pretax Margin (5Y Avg)-49.62%
Revenue / Share (Annual)$62.87
Tangible BV / Share (Annual)$87.50
Forward P/E31.61x
Price vs S&P 500 (52W)0.96%
P/E Ratio (TTM)25.48x
EPS Growth TTM (YoY)149.28%
Year-to-Date Return0.14%
5-Day Price Return6.03%
EPS Normalized (Annual)$19.57
ROA (5Y Avg)-11.34%
Net Profit Margin (Annual)31.12%
Month-to-Date Return15.63%
EBITD / Share (Annual)$16.45
Operating Margin (Annual)25.38%
LT Debt / Equity (Annual)0.32x
P/CF (TTM)129.42x
ROI (5Y Avg)-13.88%
P/E Excl Extra (TTM)25.48x
EPS Basic Excl Extra (TTM)$31.07
P/TBV (Quarterly)7.32x
P/B Ratio (Annual)7.75x
Inventory Turnover (TTM)1.71x
Pretax Margin (TTM)51.88%
Book Value / Share (Annual)$90.49
Price vs S&P 500 (13W)0.12%
Beta1.03x
P/FCF (Annual)91.11x
Revenue / Share (TTM)$62.88
ROE (TTM)22.91%
52-Week Low$456.60
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
HALOHalozyme Therapeutics, Inc. | 5.90x | 37.55% | 83.62% | 22.89% | $69.57 |
About
Argenx is a Dutch biopharmaceutical company developing antibody-based therapies for rare autoimmune and immune-mediated diseases. Its lead product, Vyvgart (efgartigimod), is FDA-approved for generalized myasthenia gravis, with the subcutaneous formulation Vyvgart Hytrulo also approved for chronic inflammatory demyelinating polyneuropathy. The company's pipeline includes candidates for primary immune thrombocytopenia, thyroid eye disease, and Sjögren's disease.